Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Prepaid Assets (2022 - 2025)

Historic Prepaid Assets for NewAmsterdam Pharma (NAMS) over the last 4 years, with Q3 2025 value amounting to $28.1 million.

  • NewAmsterdam Pharma's Prepaid Assets rose 8536.81% to $28.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.1 million, marking a year-over-year increase of 8536.81%. This contributed to the annual value of $24.3 million for FY2024, which is 28277.87% up from last year.
  • Per NewAmsterdam Pharma's latest filing, its Prepaid Assets stood at $28.1 million for Q3 2025, which was up 8536.81% from $30.7 million recorded in Q2 2025.
  • Over the past 5 years, NewAmsterdam Pharma's Prepaid Assets peaked at $30.7 million during Q2 2025, and registered a low of $6.3 million during Q2 2023.
  • Moreover, its 4-year median value for Prepaid Assets was $11.7 million (2024), whereas its average is $14.9 million.
  • As far as peak fluctuations go, NewAmsterdam Pharma's Prepaid Assets tumbled by 1896.79% in 2023, and later skyrocketed by 28277.87% in 2024.
  • Over the past 4 years, NewAmsterdam Pharma's Prepaid Assets (Quarter) stood at $7.8 million in 2022, then fell by 18.97% to $6.3 million in 2023, then soared by 282.78% to $24.3 million in 2024, then increased by 15.66% to $28.1 million in 2025.
  • Its Prepaid Assets was $28.1 million in Q3 2025, compared to $30.7 million in Q2 2025 and $8.8 million in Q1 2025.